Bedfont Scientific Release: Multi-Award Winning British Company Celebrates 10 Years Of Improving Asthma Management At The Largest Meeting Of The Respiratory World, ERS
To celebrate 10 years of improving asthma management with their NObreath® FeNO monitor, Bedfont® Scientific Ltd. are giving you the chance to win a NObreath® at the ERS Congress.
Regarded as the largest gathering of respiratory professionals worldwide, this year the European Respiratory Society (ERS) will be congregating in Milan between 9-13th September. Medical device manufacturer, Bedfont®, who launched their NObreath® FeNO monitor, for improving asthma management, at ERS 2007 are returning 10 years later to celebrate the 10th birthday of the NObreath® at the 2017 ERS Congress, by hosting a competition where one lucky winner can win their very own monitor.
Entrants simply have to take a NObreath® FeNO test and have their photo taken with their FeNO reading to be included in the prize draw. All participants will also receive a free gift and additional entries can be gained by liking and sharing their picture on social media using the hashtag #knowyourFeNO.
Using FeNO measurements to evaluate airway inflammation in asthma represents a significant advance in respiratory medicine1, but until now it has been an expensive test to deliver in everyday practice. Recommended by NICE2 and conformed to ERS/ATS guidelines3, the NObreath® FeNO monitor is the essential tool for asthma.
Lois Penhaligan, Specialist Respiratory Physiologist, at the Lung Function Laboratory in Llandough, says, “It can be used with patients who have respiratory symptoms, particularly with an unexplained cough and we are looking for the possible cause. The FeNO breath test is used for an assessment of airway inflammation, for the assessment of the effectiveness of a treatment, for example, a bronchodilator and for the management of a disease, for example, asthma.”
Jason Smith, General Manager at Bedfont Scientific Ltd, explains, “Nitric Oxide is naturally produced by the lungs to combat airway inflammation, therefore FeNO levels are higher in people with asthma and, by measuring these levels during diagnosis and management of the disease, it can improve basic asthma care. By using the NObreath® FeNO monitor in basic asthma care, the GP will be able to not only determine the type of asthma (allergic or non-allergic) allowing the correct medication to be prescribed but also differentiate between asthma and other respiratory conditions. Furthermore, the NObreath® shows patient adherence to medicine allowing GP’s to adjust and prescribe the level of medication as necessary. We are proud to have spent the past 10 years perfecting FeNO monitoring to be able to provide not only an affordable technology but also a quick, easy and non-invasive procedure for both the GP and the patient, to improve asthma management.”
-ends-
EDITOR’S NOTES
For more information on the NObreath®, the competition or to read the full terms and conditions, please visit www.bedfont.com/10yearsofNObreath®
REFERENCES
1. Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris MacLachlan, Gabrielle Monti-Sheehan, Pamela Jackson and D. Robin Taylor. Diagnosing Asthma: Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests. Am J Respir Crit Care Med Vol 169. pp 473-478, 2004.
2. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath | Guidance and guidelines | NICE [Internet]. Nice.org.uk. 2014 [cited 11 July 2017]. Available from:
https://www.nice.org.uk/guidance/dg12
3. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005; American Journal of Respiratory and Critical Care Medicine; vol. 171: 912-930;2005
COMPANY DETAILS
Established in 1976, Bedfont® Scientific Limited is a second generation family company that has specialised in the design and manufacture of exhaled breath and gas monitoring instruments for medical, scientific and industrial markets globally, for over 40 years. Bedfont® is revered as a pioneer in the breath analysis market with their products now available in over 76 countries across the world thanks to their unprecedented network of appointed distributors. Their aim is to continue innovating and improving health worldwide. Products include:
Bedfont® also strives to produce high quality consumables at the lowest possible prices; these include SteriBreath™ mouthpieces, infection control filters, non-alcohol wipes and calibration gas for all their monitors.
Regarded as the largest gathering of respiratory professionals worldwide, this year the European Respiratory Society (ERS) will be congregating in Milan between 9-13th September. Medical device manufacturer, Bedfont®, who launched their NObreath® FeNO monitor, for improving asthma management, at ERS 2007 are returning 10 years later to celebrate the 10th birthday of the NObreath® at the 2017 ERS Congress, by hosting a competition where one lucky winner can win their very own monitor.
Entrants simply have to take a NObreath® FeNO test and have their photo taken with their FeNO reading to be included in the prize draw. All participants will also receive a free gift and additional entries can be gained by liking and sharing their picture on social media using the hashtag #knowyourFeNO.
Using FeNO measurements to evaluate airway inflammation in asthma represents a significant advance in respiratory medicine1, but until now it has been an expensive test to deliver in everyday practice. Recommended by NICE2 and conformed to ERS/ATS guidelines3, the NObreath® FeNO monitor is the essential tool for asthma.
Lois Penhaligan, Specialist Respiratory Physiologist, at the Lung Function Laboratory in Llandough, says, “It can be used with patients who have respiratory symptoms, particularly with an unexplained cough and we are looking for the possible cause. The FeNO breath test is used for an assessment of airway inflammation, for the assessment of the effectiveness of a treatment, for example, a bronchodilator and for the management of a disease, for example, asthma.”
Jason Smith, General Manager at Bedfont Scientific Ltd, explains, “Nitric Oxide is naturally produced by the lungs to combat airway inflammation, therefore FeNO levels are higher in people with asthma and, by measuring these levels during diagnosis and management of the disease, it can improve basic asthma care. By using the NObreath® FeNO monitor in basic asthma care, the GP will be able to not only determine the type of asthma (allergic or non-allergic) allowing the correct medication to be prescribed but also differentiate between asthma and other respiratory conditions. Furthermore, the NObreath® shows patient adherence to medicine allowing GP’s to adjust and prescribe the level of medication as necessary. We are proud to have spent the past 10 years perfecting FeNO monitoring to be able to provide not only an affordable technology but also a quick, easy and non-invasive procedure for both the GP and the patient, to improve asthma management.”
-ends-
EDITOR’S NOTES
For more information on the NObreath®, the competition or to read the full terms and conditions, please visit www.bedfont.com/10yearsofNObreath®
REFERENCES
1. Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris MacLachlan, Gabrielle Monti-Sheehan, Pamela Jackson and D. Robin Taylor. Diagnosing Asthma: Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests. Am J Respir Crit Care Med Vol 169. pp 473-478, 2004.
2. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath | Guidance and guidelines | NICE [Internet]. Nice.org.uk. 2014 [cited 11 July 2017]. Available from:
https://www.nice.org.uk/guidance/dg12
3. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005; American Journal of Respiratory and Critical Care Medicine; vol. 171: 912-930;2005
COMPANY DETAILS
Established in 1976, Bedfont® Scientific Limited is a second generation family company that has specialised in the design and manufacture of exhaled breath and gas monitoring instruments for medical, scientific and industrial markets globally, for over 40 years. Bedfont® is revered as a pioneer in the breath analysis market with their products now available in over 76 countries across the world thanks to their unprecedented network of appointed distributors. Their aim is to continue innovating and improving health worldwide. Products include:
Bedfont® also strives to produce high quality consumables at the lowest possible prices; these include SteriBreath™ mouthpieces, infection control filters, non-alcohol wipes and calibration gas for all their monitors.